STAAR Surgical to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the first quarter ended March 28, 2025, on Wednesday, May 7, 2025 after the market close. The Company will also host an earnings call and webcast at 5:15 p.m. ET to discuss its financial results and business progress.

Event: STAAR Surgical 1Q 2025 Financial Results Webcast
Date: Wednesday, May 7, 2025
Time: 5:15 p.m. ET
Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=VN5Skdjp

The live webcast, including an option to pre-register, can be accessed at the preceding link or the “Investors” section of the STAAR website at https://investors.staar.com/. A webcast replay will be available at the same link for at least 90 days.

About STAAR Surgical

STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.EVOICL.com. To learn more about STAAR, visit www.staar.com.

We intend to use our website as a means of disclosing material non-public information about the Company and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections at investors.staar.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the Email Alerts section at investors.staar.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250423392722/en/

Investors & Media

Brian Moore

Vice President, Investor Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Investors – Asia

Niko Liu, CFA

Director, Investor Relations and Corporate Development – Asia

+852-6092-5076

nliu@staar.com

Source: STAAR Surgical Company

FAQ

When will STAAR Surgical (STAA) release Q1 2025 earnings?

STAAR Surgical will release Q1 2025 earnings on Wednesday, May 7, 2025, after market close, with a conference call scheduled for 5:15 p.m. ET.

How many ICL implants has STAA sold globally?

STAAR Surgical has sold more than 3 million ICLs across over 75 countries worldwide.

What is STAAR Surgical's main product line?

STAAR's main product is the EVO ICL™ (Implantable Collamer® Lens) family, offering vision correction through minimally invasive procedures.

Where are STAAR Surgical's (STAA) manufacturing facilities located?

STAAR Surgical operates research, development, manufacturing, and packaging facilities in California and Switzerland.